FDA Approves VIGABATRIN — Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals LLC has secured FDA approval for its generic Vigabatrin oral formulation, positioning the company to capitalize on cost-savings trends by entering the market with a potential direct competitor to branded therapies. This launch signals increased competition in the oral anti-seizure sector, likely pressuring established players on pricing and market share.